North America Upstream Bioprocessing Market Forecast to 2030 - Regional Analysis by Product Type, Workflow, Usage Type, and Mode

The North America upstream bioprocessing market was valued at US$ 3.95 billion in 2022 and is expected to reach US$ 10.60 billion by 2030; it is estimated to grow at a CAGR of 13.1% from 2022 to 2030.

Commercial Use of Single-Use Bioreactors Fuels North America Upstream Bioprocessing Market.

Various manufacturers are developing single-use bioreactors (SUBs) due to their robust build and high performance, which are necessary for the commercial manufacturing of biopharmaceuticals. The incorporation of technologies associated with biofilm formation, stirring mechanisms, bioreactor designs, and sensor systems, among others, have resulted in the increased adoption of disposable reactors at the laboratory and production scales. Single-use bioreactors are operated to manufacture next-generation cell and gene therapies, and they are suitable for continuous bioprocessing. Advancements in cell-culture processes have developed higher titers and cell densities, facilitating the adoption of SUBs.

Single-use bioreactors operate with a low risk of contamination, shorter production turnaround times, and reduced validation time. In the last few years, the use of single-use bioreactors has increased in modern biopharmaceutical processes owing to their unique ability to aid enhanced flexibility, reduce investments, and limit operational costs. Also, many companies have developed single-use bioreactors for producing a wide range of therapeutics. In March 2021, Thermo Fischer Scientific launched the 3,000 L and 5,000 L HyPerforma DynaDrive single-use bioreactors.

Sartorius AG offers a wide range of single-use bioreactors. The company provides ambr 15 for a 10-15 mL micro bioreactor scale and Biostat STR for 50-2000L. The use of single-use bioreactors is subsequently increasing in upstream bioprocessing. Thus, the increasing acceptance of single-use bioreactors for the production of therapeutics propels the upstream bioprocessing market.

North America Upstream Bioprocessing Market Overview

The upstream bioprocessing market in North America is segmented into the US, Canada, and Mexico. Market growth in North America is attributed to the increasing demand for bioreactor systems from biopharmaceutical and biotechnology companies, the prominent presence of market players, and growing R&D efforts by academic and research institutes. In addition, research activities by pharmaceutical and biotechnology companies propel the upstream bioprocessing market growth in North America.

North America Upstream Bioprocessing Market Segmentation

• The North America upstream bioprocessing market is segmented based on product type, workflow, usage type, mode, and country.
• Based on product type, the North America upstream bioprocessing market is segmented into bioreactors/fermenters, cell culture, filters, bags and containers, and others. The bioreactors/fermenters services held the largest market share in 2022.
• Based on workflow, the North America upstream bioprocessing market is categorized into media preparation, cell culture, and cell separation. The cell separation held the largest market share in 2022.
• In terms of usage type, the North America upstream bioprocessing market is bifurcated into single-use and multi-use. The single-use held a larger market share in 2022
• By mode, the North America upstream bioprocessing market is bifurcated into In-house and outsourced. The In-house held a larger market share in 2022.
• Based on country, the North America upstream bioprocessing market is segmented into the US, Canada, and Mexico. The US dominated the North America upstream bioprocessing market share in 2022.
• Thermo Fisher Scientific Inc, Esco Micro Pte Ltd, Sartorius AG, Danaher Corp, Getinge AB, Merck KGaA, Corning Inc, Entegris Inc, and PBS Biotech Inc are some of the leading companies operating in the North America upstream bioprocessing market.

Market Highlights

• Based on product type, the North America upstream bioprocessing market is segmented into bioreactors/fermenters, cell culture, filters, bags and containers, and others. The bioreactors/fermenters segment held 35.1% market share in 2022, amassing US$ 1.39 billion. It is projected to garner US$ 3.69 billion by 2030 to expand at 13.0% CAGR during 2022-2030.
• The cell separation segment held 40.1% share of North America upstream bioprocessing market in 2022, amassing US$ 1.58 billion. It is projected to garner US$ 4.43 billion by 2030 to expand at 13.7% CAGR during 2022-2030.
• The single-use segment held 55.2% share of North America upstream bioprocessing market in 2022, amassing US$ 2.18 billion. It is projected to garner US$ 5.95 billion by 2030 to expand at 13.4% CAGR during 2022-2030.
• In terms of mode, the North America upstream bioprocessing market is bifurcated into In-house and outsourced. The outsourced segment held 59.3% share of North America upstream bioprocessing market in 2022, amassing US$ 2.34 billion. It is projected to garner US$ 6.16 billion by 2030 to expand at 12.8% CAGR during 2022-2030.
• This analysis states that the US captured 83.2% share of North America upstream bioprocessing market in 2022. It was assessed at US$ 3.29 billion in 2022 and is likely to hit US$ 8.98 billion by 2030, exhibiting a CAGR of 13.4% during 2022-2030.
• In February 2022, Thermo Fisher Scientific in announced expansion for its Bioprocessing. The company has invested US$40 million to construct and maintain a manufacturing plant for single-use technologies in Millersburg, Pennsylvania. The expansion was a part of a multiyear, US$ 650 million investment to improve the company's capacity to produce bioprocessing in a flexible, scalable, and dependable manner.
• In January 2023, Sartorius collaborated with RoosterBio Inc to address purification challenges and establish scalable downstream manufacturing processes for exosome-based therapies. Through this collaboration, Sartorius and RoosterBio will provide best-in-class solutions and expertise for a human mesenchymal stem/stromal cell (hMSC) - based exosome production platform that delivers industry-leading yield, purity, and potency.

Reasons to Buy

• Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the North America upstream bioprocessing market.
• Highlights key business priorities in order to assist companies to realign their business strategies.
• The key findings and recommendations highlight crucial progressive industry trends in North America upstream bioprocessing market, thereby allowing players across the value chain to develop effective long-term strategies.
• Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
• Scrutinize in-depth North America market trends and outlook coupled with the factors driving the market, as well as those hindering it.
• Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing, and distribution.